e-learning
resources
Glasgow 2004
Monday 06.09.2004
Problems of resistance and HIV coinfection in tuberculosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Reasons for failure to control the London-based isoniazid outbreak of tuberculosis
K. Viney, G. H. Bothamley (London, United Kingdom)
Source:
Annual Congress 2004 - Problems of resistance and HIV coinfection in tuberculosis
Session:
Problems of resistance and HIV coinfection in tuberculosis
Session type:
Oral Presentation
Number:
2707
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
K. Viney, G. H. Bothamley (London, United Kingdom). Reasons for failure to control the London-based isoniazid outbreak of tuberculosis. Eur Respir J 2004; 24: Suppl. 48, 2707
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
Direct molecular testing for isoniazid and rifampicin resistance from respiratory specimens of patients with tuberculosis
Source: Annual Congress 2013 –Tuberculosis: epidemiology and public health management III
Year: 2013
Treatment with isoniazid or rifampin for latent tuberculosis infection: population-based study of hepatotoxicity, completion and costs
Source: Eur Respir J, 55 (3) 1902048; 10.1183/13993003.02048-2019
Year: 2020
Frequency of rifampicin resistance in re-treatment cases of pulmonary tuberculosis using Gene-Xpert in a tertiary care hospital tuberculosis clinic
Source: International Congress 2015 – WHO guidelines in TB and clinical practice
Year: 2015
Rifampicin and INH monoresistance prevalence among Iraqi smear positive pulmonary tuberculosis cases
Source: International Congress 2016 – Update on drug-resistant tuberculosis
Year: 2016
Resistance to pyrazinamide of
Mtb
strains in TB institute clinic
Source: Eur Respir J 2007; 30: Suppl. 51, 413s
Year: 2007
Spread of tuberculosis among household contacts of multi drug resistant tuberculosis (MDRTB) patients
Source: International Congress 2014 – Tuberculosis: epidemiology and public health
Year: 2014
Drug resistance trends and patterns of mycobacterium tuberculosis isolates from pulmonary tuberculosis patients at a tertiary care hospital in Turkey
Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences
Year: 2012
Multidrug resistance of
M. tuberculosis
and its infuence on treatment efficiency of new detected patients with pulmonary tuberculosis in penitentiary institutions of Belarus
Source: Eur Respir J 2007; 30: Suppl. 51, 272s
Year: 2007
Relapse rate of tuberculosis and related factors in Korea; by using the nationwide tuberculosis notification data
Source: Annual Congress 2012 - Tuberculosis: clinical findings II
Year: 2012
MOTT as a cause of treatment failure in pulmonary tuberculosis
Source: Annual Congress 2013 –Non-tuberculous mycobacteria: clinical management
Year: 2013
High-dose rifampicin in tuberculosis: experiences from a Dutch tuberculosis centre
Source: International Congress 2019 – Drug-resistant tuberculosis
Year: 2019
Rates of latent tuberculosis infection among medical staff in a TB hospital from Brasov, Romania
Source: Annual Congress 2007 - Gamma-interferon-based tests to diagnose tuberculosis infection and disease
Year: 2007
Tuberculosis 1995–2004: evaluation of the resistance of mycobacterium tuberculosis to anti-TBC drugs in Greece
Source: Eur Respir J 2006; 28: Suppl. 50, 589s
Year: 2006
Implementation of rapid drug-susceptibility testing for patients at high risk of multidrug-resistant tuberculosis in Cambodia
Source: Annual Congress 2013 –Diagnostic features of tuberculosis I
Year: 2013
Frequency of risk factors for multi-drug resistant tuberculosis among the patients enrolled at multi-drug resistant clinic in a tertiary care hospital, Pakistan
Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 1
Year: 2014
A comparison of drug sensitivity pattern in category-I failure versus category-I relapse pulmonary TB patients attending a tertiary care hospital in South Punjab, Pakistan. Is WHO category-II ATT regimen appropriate?
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013
Prevalence of fluoroquinolone resistance in
mycobacterium tuberculosis
in a tertiary care hospital in India
Source: International Congress 2014 – Mycobacterium tuberculosis infection and disease: clinical epidemiology 1
Year: 2014
Multi drug resistant (rifampicin + isoniazid) pulmonary tuberculosis – a challenge for a developing country specially co-infected with HIV
Source: Eur Respir J 2007; 30: Suppl. 51, 421s
Year: 2007
Treatment outcomes among multidrug-resistant tuberculosis (MDR-TB) cases at a referral hospital of infectious diseases in Italy
Source: International Congress 2016 – Update on drug-resistant tuberculosis
Year: 2016
Effectiveness of intravenous isoniazid and ethambutol administration in patients with new smear positive drug-susceptible pulmonary tuberculosis with tuberculous meningoencephalitis and HIV co-infection in the intensive phase of treatment
Source: International Congress 2019 – Tuberculosis: treatment and management
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept